Loading company…
Oncoinvent AS develops radiopharmaceuticals for cancer, including Radspherin, a targeted alpha therapy in clinical trials.
Founded in 2010 and headquartered in Oslo, Norway, Oncoinvent AS develops radiopharmaceuticals that deliver targeted alpha therapy to tumors while limiting harm to healthy tissue. Its lead product Radspherin is in clinical trials and is aimed at hospitals and oncology centers in Europe and North America. The company raised NOK 250 million in Pre-IPO funding as of June 29, 2021, from investors including Canica and Hadean Ventures. Listed stage: Late stage.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in